Super CBD To the Rescue? This Company Thinks So

Photo by Kindel Media from Pexels

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

With everything it can do, MyMD Pharmaceuticals Inc. MYMD says that it might make more sense to call its new product Supera-CBD by “Super CBD.”

Manufactured by the clinical-stage pharmaceutical company, Supera-CBD is a novel synthetic cannabidiol analog that in preclinical studies is dramatically more potent than plant-based CBDs — offering a more pure, Food and Drug Administration (FDA)-approved drug for patients in the future.

CBD has notably exploded on the pharmaceutical scene in the last few years, finding benefits in treating a wide variety of disorders and diseases like anxiety, insomnia, chronic pain, and arthritis. Companies in the space like Charlotte’s Web Holdings CWBHF, CV Sciences Inc. CVSI, and GW Pharmaceuticals PLC GWPH are continually working on CBD products that could rival those in the traditional pharmaceutical industry. CBD may have broad therapeutic properties across a range of neuropsychiatric disorders but without the psychoactive effects of THC, the intoxicating component of marijuana. Supera-CBD has specifically demonstrated anti-anxiety effects with much higher potency and efficacy than plant-derived CBD.

MyMD states that not only does Supera-CBD have improved cannabinoid receptor type 2 (CB-2) binding strength, the receptor that is involved in anti-inflammatory actions, but it activates the CB2 receptor thousands of times more effectively than CBD. Supera-CBD is also approximately 7 to 8 times more effective than plant-based CBD in inhibiting monoamine B (MAO-B) that can contribute to addiction and Alzheimer’s disease. 

It is chemically similar to cannabidiol; the main difference is that the cyclohexane ring is replaced with a cyclopentene ring. It is produced in a controlled lab environment, which allows for purity without being contaminated in comparison to plant-based CBD.

In addition, Supera-CBD could address unmet needs in patients with epilepsy and chronic pain. Around 3 to 4 million people suffer from epilepsy a year, with not many therapies adequately controlling the disorder. However, because Supera-CBD potently activates CB2, and can possibly reduce the MAO-B activity more than traditional CBD, it can help to regulate these neurotransmitters. 

Nearly 50 million people each year are also affected by chronic pain, with therapeutic interventions ranging from Tylenol and Motrin to more serious medications like opioids. Supera-CBD has shown that it binds to different opioid receptors just as well— if not better than —traditional CBD, which could make it a promising treatment prospect. Opioid receptors are guanine nucleotide-binding protein-coupled receptors (G Protein) expressed in the brain, spinal cord, peripheral neurons, and digestive tract.

The hope is that through the FDA, Supera-CBD could be available in a prescription form for chronic pain and other psychiatric applications. It would be entering a CBD market with growth potential estimated at around $800 billion over the next 15 to 20 years.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.